AUS
NZ
UK
CA
USA
IND
_06_04_2026_00_29_48_108019.jpg)
Highlights
- Orthocell Ltd. (ASX:OCC) receives a A$3.18 million R&D tax refund, boosting its cash reserves to A$33 million.
- The company is preparing for a US market entry with its innovative medical devices.
- A strategic global expansion is underway, including successful product clearances and promising growth potential.
Orthocell Ltd. (ASX:OCC), a leader in regenerative medicine, has strengthened its position in the global healthcare market by securing a substantial A$3.18 million research and development (R&D) tax refund from the Australian Government. This addition increases the company’s cash reserves to an impressive A$33 million, further fortifying its war chest as it advances its commercialization strategy worldwide.
Orthocell specializes in the repair of bone and soft tissue injuries through its innovative CelGro™ platform. The company focuses on collagen medical devices that facilitate tissue reconstruction and healing for both dental and orthopaedic applications. Its products, including the breakthrough Striate+™, Remplir™, and SmrtGraft™, demonstrate considerable potential in the expanding regenerative medicine sector.
A major milestone for Orthocell is its entry into the U.S. market. The company is on track for FDA clearance, positioning itself to introduce Remplir™ to the U.S. market in late March or early April 2025. Orthocell CEO, Paul Anderson, expressed excitement about the opportunity, emphasizing the significant growth the U.S. market—valued at US$1.6 billion—offers to the company. With a strong pipeline and revenue growth already evident in existing markets, Orthocell Ltd. expects this next phase of expansion to significantly increase its revenue potential.
Orthocell’s offerings have also earned clearance across several international markets. Striate+™ has already received approval for dental guided bone regeneration (GBR) applications in key markets, including the U.S. (510k), Canada (MDL), and Europe (CE Mark). The company is also expanding the clinical availability of its tendon repair product, SmrtGraft™, in Australia under Special Access schemes and clinical trials, while Remplir™ is already approved in Australia, New Zealand, and Singapore.
Another exciting development lies within the company’s autologous cell therapies aimed at regenerating damaged tendon and cartilage tissue. The ongoing acceleration of the tendon cell therapy program in the U.S. and engagement with the FDA signals Orthocell’s commitment to unlocking future commercial opportunities in this lucrative space.
With a strong foundation, an expanding product portfolio, and strategic focus on high-growth international markets, Orthocell Ltd. is positioning itself for significant achievements in the global medical device market.
